Myelosuppression var almindeligvis reversibel og kunne oftest håndteres ved midlertidigt at afbryde dasatinib eller ved dosisreduktion (se pkt.
4 reversible and usually managed by withholding dasatinib temporarily or by dose reduction (see sections 4.2 and 4.8).